| BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk |
NCT01620424: Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes |
|
|
| Completed | 1 | 10 | Japan | biphasic insulin aspart 30, biphasic insulin aspart 50 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 04/01 | 04/01 | | |
NCT01865305: Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes |
|
|
| Completed | 1 | 59 | Europe | insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50, insulin degludec, insulin aspart, biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 02/07 | 02/07 | | |
NCT01538511: Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers |
|
|
| Completed | 1 | 59 | Japan | biphasic insulin aspart 70, biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 03/07 | 03/07 | | |
NCT00825253: Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes |
|
|
| Completed | 1 | 24 | Europe | biphasic insulin aspart 30, biphasic human insulin 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 05/07 | 05/07 | | |
NCT00824668: Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes |
|
|
| Completed | 1 | 24 | Europe | biphasic insulin aspart 30, insulin glargine, insulin glulisine | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 10/07 | 10/07 | | |
